379-54-4

Basic information

• Product Name: 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene)
• Synonyms: 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene);Benzene, 1,1'-(chlorophenylMethylene)bis[4-fluoro-
• CAS NO: 379-54-4
• Molecular Formula: C₁₉H₁₃ClF₂
• Molecular Weight: 314.76
• Mol File: 379-54-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 385.614 °C at 760 mmHg
• Flash Point: 222.279 °C
• Appearance: /
• Density: 1.246
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene)(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene)(379-54-4)
• EPA Substance Registry System: 4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene)(379-54-4)

Safety Data

• Hazardous Substances Data: 379-54-4(Hazardous Substances Data)

Usage

General Description

4,4'-(Chloro(phenyl)methylene)bis(fluorobenzene) is a chemical compound often used in materials science research or industry as an intermediate substance in various chemical reactions. Its structural formula involves bonded phenyl groups, chlorine, and fluorine atoms. This chemical's structure gives it specific properties, like a certain level of reactivity, stability, polarity, and more. It is notable for its complexity, since it has both halogen and aromatic features. The handling of this compound requires specific precautions due to potential hazards associated with its components, especially chlorine and fluorine. Hence, it must be managed by individuals trained in chemistry who have knowledge of the safety protocols involved with handling such substances.

InChI:InChI=1/C19H13ClF2/c20-19(14-4-2-1-3-5-14,15-6-10-17(21)11-7-15)16-8-12-18(22)13-9-16/h1-13H

Upstream product

• 93-58-3 benzoic acid methyl ester 
• 379-55-5 bis(4-fluorophenyl)phenylmethanol 

Downstream Products

• 289656-82-2 bis(4-fluorophenyl)phenylacetonitrile 
• 90173-62-9 Trifluoro-acetic acid bis-(4-fluoro-phenyl)-phenyl-methyl ester 
• 103193-96-0 CDD₃₅₄₃ 

Relevant articles and documents

Novel inhibitors of the gardos channel for the treatment of sickle cell disease

Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.

Influence of some novel N-substituted azoles and pyridines on rat hepatic CYP3A activity

A series of N-substituted heteroaromatic compounds structurally related to clotrimazole was synthesized, and the effects of these compounds on ethosuximide clearance in rats were determined as a measure of their abilities to induce cytochrome P4503A (CYP3A) activity. Ethosuximide clearance and in vitro erythromycin N-demethylase activity were shown to correlate. In this series, imidazole or other related heteroaromatic 'head groups' were linked to triphenylmethane or other phenylmethane derivatives. Within the series, it was found that 1-triphenylmethane-substituted imidazoles elicited the greatest increase in CYP3A activity, and that among the triphenylmethyl-substituted imidazoles, the highest activities were achieved by the substitution of F- or Cl- in either the meta or para position of one of the phenyl rings. Diphenylmethylsubstituted pyridine was effectively devoid of activity. Compounds eliciting the largest increase in CYP3A activity (viz. 1-[(3-fluorophenyl)diphenylmethyl]imidazole, 1-[(4- fluorophenyl)diphenylmethyl]imidazole, and 1-[tri-(4- fluorophenyl)methyl]imidazole) produced little or no increase in ethoxyresorufin O-dealkylase (EROD) activity (i.e. CYP1A), whereas benzylimidazole, which elicited only a small increase in CYP3A activity, produced an almost 9-fold increase in CYP1A activity. For a series of eleven compounds exhibiting a wide range of influence on CYP3A activity, a positive correlation was found between ethosuximide clearance and hepatic CYP3A mRNA levels.